| abstract |
Disclosed is a drug that inhibits EGFR polypeptide activity for use in the treatment of neuropathic pain. The drug has no cancer or has not previously been treated for cancer, and the treated subject does not exhibit symptoms of neuropathic pain, said treatment comprising Attenuating or modulating the symptoms of disabling pain, or the treated subject has cancer, exhibits symptoms of neuropathic pain, and the treatment is independent of tumor treatment Attenuate or modulate symptoms of neuropathic pain. [Selection figure] None |